FLUTICASONE DELIVERY COMPOSITIONS, DEVICES AND METHODS
Disclosed are medicinal compositions, and devices, methods and systems which use same, comprising a carrier and at least one medicinally active compound, said carrier comprising at least 1234ze(E) and ethanol.
1 . A pharmaceutical composition comprising:
a. fine particles of fluticasone;
b. a carrier in which said fine particles of fluticasone are suspended, said carrier comprising: (i) from greater than 95% by weight to less than 99.5% by weight of HFO-1234ze(E); and (ii) from greater than 0.5% by weight to less than 5% by weight of ethanol.
2 . The pharmaceutical composition of claim 1 further comprising polyethylene glycol (“PEG”).
3 . The pharmaceutical composition of claim 2 wherein said PEG has an average molecular weight of from about 300 to about 1200.
4 . The pharmaceutical composition of claim 2 wherein said PEG has an average molecular weight of about 1000.
5 . The pharmaceutical composition of claim 2 wherein said PEG has an average molecular weight of from about 400.
6 . The pharmaceutical composition of claim 1 wherein said carrier comprises: (i) from greater than 96% by weight to less than 99.5% by weight of HFO-1234ze(E); and (ii) from greater than 0.5% by weight to less than 4% by weight of ethanol.
7 . The pharmaceutical composition of claim 1 wherein said carrier comprises: (i) from greater than 97% by weight to less than 99.5% by weight of HFO-1234ze(E); and (ii) from greater than 0.5% by weight to less than 3% by weight of ethanol.
8 . The pharmaceutical composition of claim 1 wherein said carrier comprises: (i) from greater than 98% by weight to less than 99.5% by weight of HFO-1234ze(E); and (ii) from greater than 0.5% by weight to less than 2% by weight of ethanol.
9 . The pharmaceutical composition of claim 1 wherein said carrier comprises: (i) about 99% by weight of HFO-1234ze(E); and (ii) about 1% by weight of ethanol.
10 . The pharmaceutical composition of claim 1 wherein said pharmaceutical composition has a TSI stability at 25 seconds of 25 or less.
11 . The pharmaceutical composition of claim 1 wherein said pharmaceutical composition has a TSI stability at 25 seconds of 20 or less.
12 . The pharmaceutical composition of claim 1 wherein said pharmaceutical composition has a TSI stability at 25 seconds of 18 or less.
13 . The pharmaceutical composition of claim 2 wherein said carrier comprises from greater than 0.001% by weight to less than 0.01% by weight of said PEG.
14 . The pharmaceutical composition of claim 2 wherein said carrier comprises from greater than 0.001% by weight to less than 0.0075% by weight of said PEG.
15 . The pharmaceutical composition of claim 2 wherein said carrier comprises from greater than 0.0025% by weight to less than 0.0075% by weight of said PEG.
16 . The pharmaceutical composition of claim 2 wherein said carrier comprises from greater than 0.004% by weight to less than 0.006% by weight of said PEG.
17 . The pharmaceutical composition of claim 1 wherein said fine particles of fluticasone comprise fluticasone propionate.
18 . The pharmaceutical composition of claim 1 wherein said fine particles of fluticasone consist essentially of fluticasone propionate.
19 . The pharmaceutical composition of any of claim 1 wherein said fine particles of fluticasone consist of fluticasone propionate.
20 . An MDI containing a pharmaceutical composition of claim 1 .